Characterization and bioactive component analysis of filamentous bacterium XJ-16.

Ke Jiang, Ruoxuan Bai, Xianglian Luo, Ting Gao, Fangxu Xu, Hongxin Zhao, Dianpeng Zhang

Abstract read

In one paragraph

Article in Biotechnology notes (Amsterdam, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ke JiangZhejiang Province Key Laboratory of Plant Secondary Metabolism and Regulation, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.

Ruoxuan BaiZhejiang Province Key Laboratory of Plant Secondary Metabolism and Regulation, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.

Xianglian LuoLiaoning Province Key Laboratory of Functional Cordyceps Militaris, Experimental Teaching Center, Shenyang Normal University, Shenyang, China.

Ting GaoZhejiang Province Key Laboratory of Plant Secondary Metabolism and Regulation, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.

Fangxu XuLiaoning Province Key Laboratory of Functional Cordyceps Militaris, Experimental Teaching Center, Shenyang Normal University, Shenyang, China.

Hongxin ZhaoZhejiang Province Key Laboratory of Plant Secondary Metabolism and Regulation, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.

Dianpeng ZhangBeijing Academy of Agriculture and Forestry Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Actinomycetes, which can produce a variety of bioactive compounds in the metabolic process, is one of the important sources of novel drugs, enzymes, anti-tumor drugs and enzyme inhibitors. It has been the focus of researchers to find and develop

Indexed as

ActinomyceteAntibacterial active substanceBiological activitySeparation and purificationStrain XJ-16

Identifiers

PMID39416907

DOI10.1016/j.biotno.2023.03.001

PMCPMC11446373

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.